Will Librela Safety Scrutiny and Guidance Cut Change Zoetis' (ZTS) Long-Term Narrative?

• In recent weeks, Zoetis Inc. has faced renewed scrutiny over its osteoarthritis drug Librela, with management cutting full-year guidance and committing to provide science-based evidence addressing safety concerns raised through social media and lawsuits.
• At a series of March healthcare conferences featuring CEO Kristin C. Peck and CFO Wetteny N. Joseph, the company has used its high-profile platform to directly address questions about Librela’s risk–benefit profile and the resilience of its broader innovation pipeline.
• Next, we’ll examine how the renewed focus on Librela’s safety profile could influence Zoetis’s long-term investment narrative and growth assumptions.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

Zoetis Investment Narrative Recap

To own Zoetis, you need to believe in the long term value of animal health, supported by a broad portfolio across companion animals and livestock. Right now, the key near term catalyst and risk both sit in the osteoarthritis pain franchise, where renewed scrutiny of Librela and the guidance cut have sharpened attention on safety perceptions and potential adoption headwinds. How management responds to these concerns could influence confidence in Zoetis’s wider innovation engine.

The company’s February 2026 guidance, calling for US$9.825 billion to US$10.025 billion in revenue and US$6.65 to US$6.75 in diluted EPS, is central to this discussion. Those targets were set before the latest Librela headlines, so investors will likely watch upcoming conference commentary, including CEO Kristin Peck’s appearance at the KeyBanc Healthcare Forum, for any signs of how Librela related developments might affect execution against that outlook.

Yet investors should be aware that if Librela adoption stalls or legal scrutiny intensifies, the impact on Zoetis’s long term OA pain opportunity could be much larger than...

Read the full narrative on Zoetis (it's free!)

Zoetis’ narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028. This requires 5.2% yearly revenue growth and about a $0.6 billion earnings increase from $2.6 billion today.

Uncover how Zoetis' forecasts yield a $151.00 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming Zoetis could reach about US$11.4 billion in revenue and US$3.4 billion in earnings by 2028, which is far more upbeat than consensus, especially if Librela related safety concerns persist and OA adoption proves slower than those forecasts anticipated.

Explore 9 other fair value estimates on Zoetis - why the stock might be worth just $130.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zoetis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com